Toxicological and Pharmacological Effects of VKOR Inhibitors by Miyamoto, Yohei
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 16
Toxicological and Pharmacological Effects of VKOR
Inhibitors
Yohei Miyamoto
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/63512
Provisional chapter
Toxicological and Pharmacological Effects of VKOR
Inhibitors
Yohei Miyamoto
Additional information is available at the end of the chapter
Abstract
Vitamin  K1  2,3-epoxide  reductase  (VKOR)  inhibition  is  the  main  pharmacological
effect  of  warfarin,  an  anticoagulant  that  is  typically  used  in  the  prevention  of
thrombosis  and  thromboembolism.  The  repeated  oral  administration  of  sodium
dehydroacetate (DHA-S), which has been used as a food additive, preservative, and
antimicrobial agent, induced severe hemorrhage in multiple organs and prolonged
blood coagulation factors with VKOR inhibition in rats. On the other hand, VKOR
and the vitamin K–dependent growth arrest–specific gene 6 (Gas6)/Axl pathway play
a  key  role  in  mesangial  cell  proliferation  in  glomerulonephritis  (GN).  We  herein
indicated the potential of the VKOR inhibitor, 3-acetyl-5-methyltetronic acid (AMT),
to prevent the proliferation of glomerular mesangial cells and suppress the progres-
sion of GN. DHA-S-induced hemorrhage was caused by the depletion of blood VK,
associated with any factors including VKOR inhibition. The novel VKOR inhibitor,
AMT, reduced renal mesangial cell proliferation and may be a supportive treatment
for GN.
Keywords: 3-acetyl-5-methyltetronic acid (AMT), hemorrhage, glomerulonephritis,
sodium dehydroacetate (DHA-S), vitamin K1 2,3-epoxide reductase (VKOR)
1. Introduction
The anticoagulant warfarin, which has a coumarin structure, causes hemorrhage by inhibiting
the vitamin K (VK)–dependent synthesis of blood coagulation factors [1]. Blood coagulation
factors undergo γ-carboxylation and have the ability to bind to calcium ions on the platelet
surface, under the presence of VK and molecular oxygen. Vitamin K1 2,3-epoxide (VKO), which
is produced while this γ-carboxylation, is converted to vitamin K1 (VK1) by vitamin K1 2,3-
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epoxide reductase (VKOR) and is then recycled. Warfarin arrests the regeneration of VK by
inhibiting VKOR and induces hemorrhage due to a VK deficiency.
Sodium dehydroacetate (DHA-S) has a wide spectrum of antimicrobial activity that accounts
for its use in cosmetic products, as a preservative, and as an antimicrobial agent [2]. In Japan,
it has also been used as a food preservative for cheese, butter, and margarine at a concentration
of 0.5 g/kg or less as dehydroacetic acid [3, 4]. This concentration is the highest dose allowed
under the Food Sanitation Law; however, the risk assessment of DHA-S has not been suffi-
ciently performed for a food additive, and its acceptable daily intake has not yet been estab-
lished. On the other hand, the toxicity of DHA-S has been widely studied. In an acute toxicity
study of DHA-S using dogs, clinical signs such as salivation, vomiting, convulsions, and ataxia
were reported [5]. In a subchronic toxicity study of DHA-S using dogs, body weight loss, gastric
hemorrhage, and an increase in blood urea nitrogen were observed [6]. These findings were
considered to be primarily due to a lack of appetite and subsequent weight loss [6]. However,
the main structure of DHA-S, 2H-pyran-2-on, is included in a coumarin structure. It is reported
that some derivatives of 4-hydroxy-2-pyrone, which includes similar structure of DHA-S,
exhibit anti-blood coagulant activities in rats [7]. These findings suggest that DHA-S also shows
the anticoagulant activity. Therefore, we investigated the effects of repeated administration of
DHA-S in rats, and the amelioration by VK against DHA-S-induced hemorrhage [8].
In Thy-1 glomerulonephritis (GN) rats, the expression of growth arrest-specific gene 6 (Gas6)
and Axl was found to be markedly increased in glomeruli and paralleled the proliferation of
mesangial cells [9, 10]. VKOR is also related with mesangial cell proliferation through the
vitamin K–dependent activation of Gas6 [10]. Gas6 is as an autocrine growth factor for
mesangial cells through binding to its cell surface receptor Axl. These findings suggest that
the Gas6/Axl pathway plays an important role in mesangial cell proliferation in GN [11]. VKOR
inhibitors including warfarin is effective at blocking mesangial cell proliferation and improv-
ing renal function [11]; however, it inhibits the production of blood coagulation factors in the
liver and has been able to cause bleeding [12]. Therefore, low-dose treatments of warfarin are
used in renal failure patients, and the control of its blood concentration or the conformation
of blood coagulation activities have to been required [13]. We are discovering new compounds
that inhibit mesangial cell proliferation, but not hepatic production of blood coagulation
factors using Thy-1 GN rats Table 2. Thy-1 GN rats have been used as an acute model of GN
accompanied with mesangial cell proliferation, matrix expansion, and moderate decline of
renal function [14]. We indicated the potential of a new VKOR inhibitor, 3-acetyl-5-methylte-
tronic acid (AMT), as an inhibitor of mesangial cell proliferation and suppressor of renal
disease [15].
2. Main body
In a 14-day repeated toxicity study using rats, animals that received 200 or 400 mg/kg/day of
DHA-S died from severe hemorrhage in various organs, such as the stomach, intestines, testes,
epididymides, subcutaneous tissue, and subdural area. The profile of hemorrhage caused by
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DHA-S, which occurred in multiple organs and showed differences in sensitivity among
individuals, was similar to that caused by warfarin. The prothrombin time (PT) and activated
partial thromboplastin time (APTT) were significantly prolonged in each surviving rat in the
100 and 200 mg/kg/day groups (Figure 1). These results indicated that the repeated dosing of
DHA-S-induced hemorrhage in rats [8].
Figure 1. Effects on PT and APTT in male rats received the repeated oral administration of DHA-S at doses of 50, 100,
and 200 mg/kg/day. ( ) Vehicle; ( ) 50 mg/kg/day; ( ) 100 mg/kg/day; ( ) 200 mg/kg/day. Each value is presented
as the mean ± SD. * P < 0.05, ** P < 0.01: Significantly different from controls at 5% and 1%.
On the other hand, DHA-S-treated rats showed no significant decrease in PLT. In the histopa-
thological examination of the liver, marked changes, such as fibrin thrombi in the vascular
system and single cell necrosis, were not observed. Therefore, hemorrhage was assumed to be
caused by a deficiency in VK. In order to demonstrate this hypothesis, the effects of VK on
hemorrhage were investigated using rats that received a single subcutaneous injection of VK2
following the repeated oral administration of DHA-S at 200 mg/kg/day for 5 days. In rats,
dietary VK1 was converted to menadione in the gut and menadione was absorbed and
converted to VK2 [16]. Consequently, VK2 (menaquinone-4) reached a maximum concentration
in the liver in rats faster than after the intravenous or intraperitoneal administration of VK1
[17]. VK2 was also reported to exert stronger preventive effects against hemorrhage than other
VK products, such as VK1 and VK3. As a result, DHA-S prolonged blood coagulation param-
eters (PT, APTT, the thrombo test (TTO), and hepaplastin test (HPT), in rats that received 200
mg/kg/day for 5 days (Figure 2). However, the prolongation of these parameters was sup-
pressed in animals injected subcutaneously with VK2 after DHA-S dosing. Since TTO and HPT
are sensitive indexes of a deficiency in VK-dependent blood coagulation factors [18, 19], it was
concluded that DHA-S induced hemorrhage via a deficiency in VK.
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Figure 2. Effects on blood coagulation parameters (PT, APTT, TTO, and HPT) in male rats received DHA-S for 5 days
following a single subcutaneous injection of vitamin K2 (VK2). ( ) Vehicle; ( ) DHA-S at 200 mg/kg/day for 5 days;
( ) DHA-S at 200 mg/kg/day for 5 days and VK2 at 1 mg/kg after the final DHA-S dosing on day 5. Each value is
presented as the mean ± SD. ** P < 0.01: Significantly different from controls at 1%.
A VK deficiency is caused by anticoagulants, hepatobiliary disease, the inhibition of VK
production by the intestinal flora, and the poor absorption of VK from the gut [20]. Prolonga-
tion of PT and APTT were also observed in the 100 mg/kg group, which did not significantly
decrease in body weight. In the macroscopic observation of surviving rats, no remarkable
changes were detected in the gastro-intestinal tracts. While DHA-S exhibited weak antimicro-
bial activity against obligatory anaerobes, the major intestinal flora [2], the effects of a high
dose of DHA-S on the intestinal flora currently remain unknown. VK is a cofactor for enzymatic
conversion (γ-carboxylation) of glutamic acid residues in the inactive precursors of VK-
dependent proteins (blood coagulation factors) in order to convert them to their active forms.
In VK cycle, accompanying with this reaction, VK1H2 (hydroquinone form), is oxidized to VKO,
and subsequently reduced the VK1 (quinone form). The anticoagulant warfarin is known to be
a VK antagonist and is used as a rodenticide to induce hemorrhage in rats [21]. A warfarin-
induced VK deficiency occurs through the inhibition of VKOR that then converts VKO to the
quinone form of VK1 in the VK cycle [1, 22, 23]. The coumarin structure of warfarin involves
the main structure of DHA-S, and some derivatives of 4-hydroxy-2-pyrone have been reported
to exhibit anticoagulant activities in rats [7]. The hemorrhage induced by DHA-S, which occurs
in multiple organs and shows individual differences in sensitivity, is similar to that by warfarin.
The effects of DHA-S on VKOR activity were investigated using male rat liver microsomes.
VKOR activity, expressed as the quantitative amount of VK1 converted from VKO, was induced
in vitro by a VKOR reaction and the inhibition by each compound was estimated from the
percentage of VKOR activity measured in an identical incubation containing no compound.
DHA-S and warfarin both showed dose-dependent suppression of VKOR activities, and DHA-
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S inhibited clearly VKOR activity as well as warfarin [8]. The IC50 values of DHA-S and warfarin
were 3149 and 2.15 μmol/L, respectively. The inhibitory effect of DHA-S on VKOR activity was
expected to be approximately 1400-fold as compared with warfarin. The treatment with DHA-
S at dose of 100 mg/kg (480 μmol/kg) for 5 days prolonged PT and APTT in rats by approxi-
mately 1.3-fold against that of the control. On the other hand, the repeated oral administration
of warfarin at 0.2 mg/kg (0.6 μmol/kg) for 5 days elongated PT in rats [24]. Furthermore, TTO
activity was reduced by approximately 50% in rats under a controlled rate (0.15 μmol/kg/day)
of warfarin administration by osmotic pumps implanted subcutaneously [25]. The dose which
DHA-S inhibits blood coagulation factors in rats is 800–3200-fold higher than that of warfarin.
This fact explains the difference between the VKOR inhibitory activities of DHA-S and
warfarin. In humans, the daily intake level of DHA is estimated to be 0.0303 mg [26] which is
approximately 16,500-fold less than that inducing hemorrhage in rats. Therefore, the potential
of DHA-S to induce hemorrhage in humans is low [8]. In conclusion, DHA-S induces severe
hemorrhage in rats through the depletion of blood VK associated with any factors including
the inhibition of VKOR [8].
On the other hand, we demonstrated that the novel VKOR inhibitor, AMT prevented renal
mesangial cell proliferation, and then suppressed glomerular injury in Thy-1 GN rats [15]. The
low molecular weight compound, AMT exhibits inhibitory activity against rat liver and
kidney VKOR in vitro at IC50 values of 3.18 and 3.20 nmol/mL, respectively [15]. VKOR is a
protein that converts the epoxide of VK back to VK, a co-factor that is essential for the post-
translational γ-carboxylation of several blood coagulation factors, and is also involved in
mesangial cell proliferation via the VK-dependent activation of the Gas6/Axl pathway [11,
27]. The gene of VKOR was identified and VKOR was expressed ubiquitously in the liver,
kidney, lung, heart, and skeletal muscle [27, 28]. However, no information exists on the specific
isoforms of VKOR in any tissue. Therefore, AMT showed no selectivity in its inhibitory activity
toward rat kidney and liver VKOR. It is known that there are no selective compounds including
warfarin. These findings suggest that kidney and liver VKOR have similar substrate recogni-
tion or that there was no specific isoform of VKOR, at least in the rat liver and kidney.
In Thy-1 GN rats, kidney weights decreased significantly in a dose-dependent manner after
the AMT treatment (Table 1). No significant changes were observed in light microscopy, while
the slight enlargement and rough surface of kidneys were noted in the control [15]. Renal
enlargement followed by mesangial cell proliferation is frequently observed in Thy-1 GN rats
and is mostly due to edema associated with inflammation [29, 30]. Thickening of the glomer-
ular basement membrane and fibrocellular crescent of the glomerulus were histopathologically
suppressed by the AMT treatment (Figure 3). These pathological findings associated with the
progression of renal injury [14, 29] may be caused by the inhibitory effects of AMT on mesangial
cell proliferation and glomerular inflammation [15]. Additionally, tubular degeneration such
as hyaline casts, hyaline droplets, tubular dilatation, and basophilic tubules followed by
glomerular damage were found to be dose-dependently suppressed by the AMT treatment in
Thy-1 GN rats [15].
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Relative kidney weight (g/100 g body weight)
Group Dose Right Left Total
Normala – 0.377 ± 0.033 (6) 0.383 ± 0.025 (6) 0.760 ± 0.057 (6)
Thy-1-administered 0 mg/kg (control) 0.478 ± 0.016 (6) 0.469 ± 0.017 (6) 0.947 ± 0.033 (6)
10 mg/kg 0.417 ± 0.016* (6) 0.409 ± 0.017* (6) 0.826 ± 0.033* (6)
30 mg/kg 0.395 ± 0.009** (6) 0.383 ± 0.010** (6) 0.779 ± 0.018** (6)
Values are means ± S.E. for the numbers of rats indicated in parentheses.
*,** Significantly different from control, P < 0.05 (*), P < 0.01 (**).
aNormal rats without anti-Thy-1 injection.
Table 1. Relative organ weights of kidney following after 12-day repeated intravenous administrations of AMT (0, 10
and 30 mg/kg/day) in Thy-1 glomerulonephritis rats.
Figure 3. Light microscope of kidneys after the 12-day repeated intravenous administration of AMT to Thy-1 GN rats.
Periodic acid-Schiff (PAS)-stained sections show thickening of the glomerular basement membrane and fibrocellular
crescent of the glomerulus in the 0 mg/kg group (a), and no significant change in the glomerulus or tubules in the 30
mg/kg group (b).
The Thy-1 GN rat is one of the reversible models of kidney injury. An anti-Thy-1 injection
induces the destruction of glomerular mesangial cells and leads to the thickening of the
glomerular basement membrane in rats [14, 31]. A decline in renal function has been observed
1 week after its injection; however, renal function recovers completely 5–6 weeks later [14, 31].
In addition, marked mesangial cell proliferation has been reported in patients with chronic
GN [32, 33]. Therefore, the Thy-1 GN rat is considered to be an adequate animal model of GN
and is suitable for assessing the effectiveness of chemical compounds as suppressors toward
the disease [34–36].
The typical VKOR inhibitor, warfarin, inhibits mesangial cell proliferation and prevents the
progression of kidney diseases by inhibition of the activation of the Gas6/Axl pathway [11].
Both levels of Gas6 and its receptor Axl increased in various kidney diseases [11, 37]. Gas6 is
activated by vitamin K–dependent γ-carboxylase, which converts the glutamic acid of the N-
terminal domain of Gas6 to the γ-carboxyl glutamate. VKOR regulates the concentration of
VK in the VK cycle, and then controls γ-carboxylase activity [9, 10]. Therefore, VKOR controls
the activation of the Gas6/Axl pathway, and its inhibition has potential as a therapeutic
treatment for kidney diseases [11]. Warfarin has been used as a supportive medication for
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human GN in clinical. However, it inhibits not only renal VKOR, but also hepatic VKOR, which
is involved in the production of blood coagulation factors, thereby increasing the bleeding risk
[12].
In our experiment, following the 14-day repeated oral administration of AMT up to 1500 mg/
kg to rats, no significant toxicities including hemorrhage and blood coagulation were noted in
our study (data not shown). AMT, which exerts potent inhibitory effects on hepatic VKOR, did
not affect blood coagulation in Thy-1 GN rats. Nevertheless, anti-inflammatory effects in
kidney were observed in the AMT-treatment group, which may be caused by the inhibition of
renal VKOR. We measured AMT concentrations in the kidney and liver after the intravenous
administration of AMT to rats. Kidney and liver concentrations of AMT 5 min after the single
intravenous administration of 30 mg/kg were 4.26 nmol/g tissue and 0.26 nmol/g tissue,
respectively [15], and revealed that the concentration in the kidney reached the IC50 value (3.2
nmol/L) against VKOR, whereas that in liver did not (3.18 nmol/L). Renal anti-inflammatory
effects and the lack of an effect on anticoagulation were both explained by VKOR inhibitory
activity and tissue concentrations of AMT in Thy-1 GN rats. AMT had no selectivity against
kidney and liver VKOR; however, the tissue distribution of AMT was unique, and its concen-
tration was higher in the kidney than in the liver. At the maximum concentration after its oral
administration, AMT concentrations were higher in the kidney than in the liver (data not
shown). AMT is very small and highly polar, and, as such, is likely to be distributed to the
kidneys and excreted. Furthermore, it has no radical scavenging potential itself (data not
shown). Therefore, the suppression of mesangial cell proliferation and glomerular inflamma-
tion in Thy-1 GN rats was considered to be based on the VKOR inhibitory effects of AMT. In
Thy-1 GN rat following the AMT treatment, creatinine clearance (CCr) significantly increased,
and the urinary albumin-to-creatinine ratio (ACR) significantly decreased [15].
0 mg/kg 10 mg/kg 30 mg/kg
Total protein (mg/day) 106 ± 24 (6) 129 ± 51 (6) 91 ± 119 (6)
Albumin (mg/day) 74.8 ± 9.1 (6) 75.9 ± 22.9 (6) 59.8 ± 19.1 (6)
Creatinine (mg/day) 8.10 ± 0.19 (6) 10.5 ± 0.9* (6) 12.8 ± 0.4** (6)
ACRa (mg/mg) 9.26 ± 1.18 (6) 6.98 ± 1.69 (6) 4.77 ± 1.61 (6)
CCrb (ml/min/kg) 1.91 ± 0.08 (6) 2.76 ± 0.22** (6) 2.87 ± 0.20** (6)
Values are means ± S.E. for the numbers of rats indicated in parentheses.
aACR is albumin-to-creatinine ratio.
bCCr is calculated from the urine creatinine concentration, urine volume and the plasma creatinine concentration.
*,** Significantly different from control, P < 0.05 (*), P < 0.01 (**).
Table 2. Urinalysis after 12-day repeated intravenous administrations of AMT (0, 10 and 30 mg/kg/day) in Thy-1
glomerulonephritis rats.
In Thy-1 rats, a marked decline in CCr and increase in ACR involved with the glomerular
disorder have been reported [9, 17, 37]. In our study, serum creatinine levels were only
suppressed by the 10 mg/kg AMT treatment, whereas urine creatinine levels were suppressed
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and CCr was subsequently increased by the 10 and 30 mg/kg treatments in Thy-1 rats. In
addition, ACR was also slightly decreased in a dose-dependent manner. Previous studies
demonstrated that ACR is the most important index in GN and accurately assesses the
progression of kidney injury [18, 24]. Therefore, we consider that the CCr and ACR to be more
sensitive than plasma and/or serum creatinine. On the other hand, no significant change was
observed in blood coagulation tests such as PT, APTT, TTO, and HPT. Based on results, AMT
suppressed glomerular mesangial cell proliferation and the progression of glomerular disease
in Thy-1 GN rats at a non-toxic dose. Recently, warfarin-related nephropathy (WRN) has been
reported in patients with and without chronic kidney disease (CKD) [38, 39]. Clinical studies
showed that mortality rates in 1 year were higher in WRN patients than in other patients. This
result coincides with previous findings of increased mortality rates in warfarin-treated chronic
hemodialysis patients [40, 41]. However, the increased mortality rate associated with WRN is
related to the complications of diabetes, hypertension, cardiovascular disease, etc., and the
mechanisms and risks of WRN currently remain unclear. Warfarin is a widely used anticoa-
gulant for thrombotic complications and increases mortality rates in CKD patients. Further
studies are necessary to assess how these complications are related to the mechanisms and
risks [41].
GN is a major process of end-stage renal disease (ESRD) along with diabetes and hypertension
[42]. However, there are no appropriate therapeutic treatments for GN. In therapy for GN,
steroids are widely used as anti-inflammation drugs for patients, particularly those with IgA
nephropathy, which is typical mesangial proliferative GN [43, 44]. As steroids reduce protei-
nuria, they prevent the progression of kidney failure. However, extensive and severe side
effects concerning the immune, circulating, and metabolic systems have been reported in
patients with steroid therapy [45, 46]. Both angiotensin-converting enzyme (ACE) inhibitors
and angiotensin receptor blockers (ARBs) are widely treated for kidney disease in patients
with diabetes and hypertension [47–49]. ACE inhibitors and ARBs control blood pressure by
inhibiting the production of angiotensin II or preventing it from binding to angiotensin II
receptors in the renin-angiotensin system, and, thus, reduce hypertension. In addition,
nonclinical and clinical studies have demonstrated that ACE inhibitors and ARBs decrease
proteinuria and prevent kidney failure [47, 50, 51]. In Thy-1 GN rats, treatments with ACE
inhibitors or ARBs were found to inhibit increases in blood pressure and proteinuria, and
subsequently the decline in renal function [52]. Persistent hypertension and glomerular
hypertension may stretch the glomerular capillary wall, and result in endothelial damage and
glomerular sclerosis, followed by a rise in protein glomerular filtration [53]. Schmieder [54]
and Mochizuki et al. [55] reported that these compounds inhibited the kidney-specific renin-
angiotensin aldosterone system and prevented end-organ damage in the kidney beyond these
antihypertensive effects. On the other hand, the VKOR inhibitor, AMT, prevents mesangial cell
proliferation in the kidneys and suppresses the progression of GN. Unfortunately, AMT is not
as effective by oral administration due to its low bioavailability. If improvements are archived
in the biological stability of AMT, which has unique pharmacokinetic properties and is
distributed to the kidney at a higher concentration than to the liver, VKOR inhibitors may be
useful for the treatment for GN, particularly in combination with existing medications such as
ACE inhibitors or ARBs.
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In conclusion, the novel VKOR inhibitor, AMT, reduced renal mesangial cell proliferation and
may be a supportive treatment for GN.
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